1240518-41-5

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Difluoro-6-methoxybenzonitrile is used as an intermediate in the synthesis of various pharmaceuticals for its potent and selective inhibitory effect on the enzyme 5-lipoxygenase. This property makes it a potential candidate for the treatment of inflammatory diseases, offering a targeted approach to managing such conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Difluoro-6-methoxybenzonitrile is utilized as a component in the development of herbicides and insecticides. Its ability to disrupt the growth and development of certain plant and insect species positions it as a valuable tool in controlling pests and unwanted vegetation, thereby contributing to more effective and targeted agricultural practices.

Upstream product

• 124-41-4 sodium methylate 
• 96606-37-0 2,4,6-trifluorobenzonitrile 
• 608515-57-7 2,4-difluoro-6-methoxybenzaldehyde 
• 67-56-1 methanol 
• 93343-10-3 3,5-difluoroanisol 

Downstream Products

• 1240518-43-7 3-{[3-amino-6-fluoro-4-(methyloxy)-1H-indazol-1-yl]methyl}benzonitrile 
• 1361330-23-5 N₁-[(3-{[6-fluoro-3-{[(3-fluoro-4-methylphenyl)sulfonyl]amino}-4-(methyloy)-1 H-indazol-1-yl]methyl}phenyl)methyl]-N₂,2-dimethylalaninamide 
• 1361330-56-4 C₃₃H₃₇F₂N₅O₇S 
• 1361330-36-0 N-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-3-fluoro-4-methylbenzenesulfonamide 
• 1361330-37-1 N-[1-{[3-(aminomethyl)phenyl]methyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-3-fluoro-4-methylbenzenesulfonamide 
• 1361330-09-7 (3R)-N-[(3-{[6-fluoro-3-{[(3-fluoro-4-methylphenyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]-3-morpholinecarboxamide 
• 1361330-10-0 (3S)-N-[(3-{[6-fluoro-3-{[(3-fluoro-4-methylphenyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]-3-morpholinecarboxamide 
• 1361330-11-1 N-[(3-{[6-fluoro-3-{[(3-fluoro-4-methylphenyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide 
• 1240518-47-1 N-[1-{[3-(aminomethyl)phenyl]methyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide formate 
• 1240517-58-1 N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-6-fluoro-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 
• 1240517-61-6 N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-6-fluoro-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide 
• 1240518-44-8 5-chloro-N-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide 
• 1240518-46-0 N-[1-{[3-(aminomethyl)phenyl]methyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide 
• 1240518-42-6 6-fluoro-4-methoxy-1H-indazol-3-amine 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE

The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reductase (DHFR) inhibito

Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists

A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists. Methoxy- or hydroxyl- containing groups were the more potent indazole C4 substituents. Only small groups were tolerated at C5, C6, or C7, with the C6 analogues being preferred. The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide. N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents. Strongly basic amino groups had low oral absorption in vivo. Less basic analogues, such as morpholines, had good oral absorption; however, they also had high clearance. The most potent compound with high absorption in two species was analogue 6 (GSK2239633A), which was selected for further development. Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II. X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramolecular interaction in the active conformation.

CC.CHEMOKINE RECEPTOR 4 ANTAGONISTS

Indazole compounds, processes for their preparation, pharmaceutical compositions containina such compounds and their use in the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.

NOVEL COMPOUNDS

Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.